Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results

Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and ...

Aurora Cannabis, Lufthansa, Saturn Oil & Gas, TUI - the twofold candidates

In the context of the Corona Pandemic, share prices came under pressure from numerous sectors and companies. The continued existence of renowned companies was at risk shortly after the announcement of measures against the spread of Covid-19. In order to prevent worse, the stat...

U.S. Energy Firm's Stock at 'Good Entry Point,' Rating Upgraded to Outperform

An update on this company's valuation is provided in a Raymond James report. In an Aug. 13 research note, analyst Pavel Molchanov reported that Raymond James boosted its rating on Chart Industries Inc. (GTLS:NASDAQ) to Outperform from Market Perform, "...

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...

Gold as a Strategic Asset - in 2019 and Beyond

Recently, the World Gold Council published a 2019 edition of a report on gold as a strategic asset . The industry organization released later the UK edition as well. Plenty of food for thought. How can the learnings from these publications strengthen our investment decisi...

Ballard Power, dynaCERT, NEL ASA - which hydrogen technology has potential?

The topic of hydrogen in mobility is currently occupying the economy, politics and investors. The stock market is looking for companies that develop solutions with the energy carrier of the future, because hydrogen can be used as an energy storage medium in electric mobility a...

Pandemics and Gold: Part 2

Teaser: The outbreak of COVID-19 has brutally reminded people of the risk of a pandemic. However, investors should never panic but look to history as a guide. We invite you thus to read our today’s article, which provides an important analysis of the history ...

Varta, Rock Tech Lithium, Millennial Lithium - all signs point to growth

ON THE AUTHOR: Carsten Mainitz The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research. Most r...
1 2 3 4 5 6 7 8 9 10 ...